Poly(ADP)-ribose polymerase (PARP) is a type of nuclear enzyme that helps repair DNA damage in cells . PARP inhibitors work by preventing cancer cells from repairing, allowing apoptosis to occur . These drugs are a type of targeted therapy used to help treat cancers. The use of these inhibitors as a control to compare THCV and HHC against the inhibitors show efficacy towards the ability for the rare cannabinoids, to be considered semi-efficient antineoplastics. The various PARP inhibitors that were tested on the same cell lines that THCV, HHC, and HHCV were tested on, had generally a weaker response than the cannabinoids, which show a less efficacy towards the treatment of pancreatic cancer unless a higher dose is used which would entail other side effects that would be counterintuitive towards a treatment. PARP inhibitors are relatively new to the market but have been used in the treatment of ovarian, fallopian tube, and peritoneal cancer . Indications that PARP Inhibitors can be used in the treatment of but not limited to lung, pancreatic, prostate, and kidney and bladder cancer are still being researched.